TNFRSF9
宿主: 人
宿主: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, FACS
TNFRSF9
宿主: 小鼠
宿主: HEK-293 Cells
Recombinant
>90 % as determined by SDS-PAGE.
应用备注
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 43.4 kDa. The protein migrates as 55-65 kDa under reducing (R) condition due to glycosylation.
限制
仅限研究用
状态
Lyophilized
缓冲液
50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH 7.5
储存条件
-20 °C
储存方法
-20°C
抗原
CD137 (TNFRSF9)
(Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
别名
4-1BB / TNFRSF9
背景
Synonyms: TNFRSF9,4-1BB,CD137,CDw137,ILA, Description: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.